Raritan’s Ortho Clinical Diagnostics Holdings plc and Quidel Corp., based in San Diego, on Dec. 23 announced entering a definitive agreement that will see Quidel acquire Ortho in a deal valued at ...

Represents noncash unrealized gains and losses resulting from the remeasurement of transactions denominated in foreign currencies primarily related to intercompany loans. (b) Represents restructuring ...

After a blockbuster two years bolstered by sales of its multiple COVID-19 diagnostics, Quidel is looking for a way to reinvest that windfall back into the business—and seems to have found it in the ...

RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ...

-- Ortho's new VITROS(R) Anti-SARS-CoV-2 Total N test detects the individual's immune response to the COVID-19 virus and is intended to help clinicians understand if their patient had a recent ...

RARITAN, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world’s largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient ...

Ortho Clinical Diagnostics is hoping to pay down a large portion of its debts by riding a wave of COVID-19 and broader in vitro lab testing demands to a $1.5 billion IPO. The company is offering 70 ...

Ortho Clinical Diagnostics Holdings plc, an in-vitro diagnostics company, has raised $1.3 billion for its IPO after pricing its 76 million shares at $17 per share. The stock began trading January 28, ...

Brings together highly complementary diagnostic portfolios with world-class technologies and platforms spanning high-throughput systems to near-patient and at-home testing. Provides Quidel’s expansive ...

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 ...

“We continue to see strong momentum in our base business as reflected in our fourth quarter 2020 Core revenue growth of 9%,” said Chris Smith, chairman and chief executive officer, Ortho Clinical ...